Abbott Laboratories

Abbott Laboratories is a global American multinational corporation with core businesses in medical devices, diagnostics, branded generic pharmaceuticals, and nutrition. Founded in the late 19th century by Wallace Calvin Abbott, a practicing physician, the company has grown into a diversified healthcare leader operating in over 160 countries. Its broad portfolio includes life-changing technologies in areas such as cardiovascular disease, diabetes management, and pediatric nutrition. Headquartered in Abbott Park, Illinois, the company is a constituent of the S&P 500 and is listed on the New York Stock Exchange.

History

The company was established in 1888 by Wallace Calvin Abbott in Chicago, initially operating as the Abbott Alkaloidal Company to produce precise, alkaloid-based medicines. A significant early milestone was the development of the first commercial intravenous saline solution in the 1920s, which established its presence in hospital care. Throughout the 20th century, it expanded through strategic acquisitions, such as Ross Laboratories in 1964, which bolstered its pediatric nutrition business with brands like Similac. Major restructuring occurred in 2013 when it separated its research-based pharmaceuticals business into a new independent company, AbbVie. More recently, it acquired St. Jude Medical in 2017, significantly expanding its footprint in the cardiovascular and neuromodulation device markets, and Alere in 2017, strengthening its position in point-of-care diagnostics.

Products and operations

The company operates through four primary business segments: Medical Devices, Diagnostics, Nutritional Products, and Established Pharmaceuticals. Its Medical Devices division is a global leader, offering a wide range of products including pacemakers and stents from its Cardiovascular portfolio, continuous glucose monitors like the FreeStyle Libre system for diabetes care, and structural heart devices such as the MitraClip. The Diagnostics segment provides a broad array of testing systems, from core laboratory analyzers used in hospitals to rapid tests for infectious diseases like COVID-19 and influenza. Its Nutritional Products include leading brands such as Similac and Pedialyte, while the Established Pharmaceuticals division markets branded generic medicines in emerging markets like India and China.

Research and development

The company maintains a significant investment in research and development, with major R&D facilities located in the United States, including at its headquarters in Abbott Park, Illinois, as well as internationally in countries like Germany and Singapore. Its innovation strategy focuses on integrating digital health technologies with medical devices, exemplified by the FreeStyle Libre system which connects to smartphone applications. Collaborative efforts with academic institutions, such as the University of California, San Francisco, and other corporations are central to its pipeline. Key recent R&D milestones include advancements in tricuspid valve repair devices, next-generation continuous glucose monitors, and novel diagnostic assays for conditions like traumatic brain injury and COVID-19 variants.

Corporate affairs

The company is led by Chairman and Chief Executive Officer Robert B. Ford, who succeeded longtime CEO Miles D. White. It is consistently recognized on lists such as the Dow Jones Sustainability Index and Fortune 500 for its corporate performance. The Abbott Fund, the company's philanthropic foundation, partners with organizations like the American Red Cross and Partners In Health on global health initiatives, focusing on areas such as malnutrition and chronic disease. Its global manufacturing and supply chain network, which faced intense scrutiny during the COVID-19 pandemic to ensure the production of tests and essential nutrition, includes major facilities in Ireland, Singapore, and the United States.

Controversies and legal issues

The company has faced numerous legal and regulatory challenges across its operations. Its Nutritional Products division encountered significant scrutiny, including a 2022 FDA investigation and a subsequent recall related to infant formula produced at its Sturgis, Michigan plant, which exacerbated a national shortage and led to a consent decree with the U.S. Department of Justice. The Medical Devices business has been involved in litigation, such as settlements over allegations of improper physician kickbacks related to its pacemaker and stent products. Furthermore, its diagnostics unit, previously part of Alere, settled allegations with the U.S. Securities and Exchange Commission concerning Foreign Corrupt Practices Act violations in countries like India and China.

Category:Medical equipment companies of the United States Category:Companies listed on the New York Stock Exchange Category:Companies based in Lake County, Illinois